Home
About Us
Resource Library
Site
Polio and prevention
Infected countries
Data and monitoring
Post-eradication
Research
Financing
Media room
You are here:
Research
>
Polio Pipeline
>
No 2, Autumn 2008
OPV efficacy
OPV delivery
Affordable IPV
Vaccine-derived polioviruses
Frequently asked questions
Polio Pipeline
No.9
No.8 Summer 2011
No.7 Winter 2011
No.6 Summer 2010
No.5 Winter 2010
No.4 Summer 2009
No.3 Winter 2009
No 2, Autumn 2008
Polio eradication
Introduction of Real Time RT-PCR
KAP studies
The role of mathematical modelling
Vaccine development
Higher-potency mOPV1 in India
Role of new and existing vaccines
Seroprevalence surveys
No.1 Summer 2008
Polio Research Committee
Grants and collaboration
Antivirals
Autumn 2008, no.2
Polio lab network, new state-of-the-art diagnostic method, the role of mathematical modelling, polio vaccine development: monovalents, seroprevalence surveys.
Download [pdf 239kb]
Articles
•
Polio eradication: why conduct research?
•
Introduction of Real Time RT-PCR into the Global Polio Laboratory Network
•
KAP studies - understanding barriers to immunization
•
The role of mathematical modelling
•
Vaccine development: monovalent OPVs
•
Higher-potency mOPV1 in India
•
Exploring the role of new and existing vaccines to support stopping transmission
•
Seroprevalence surveys to guide programmatic action